Summary of Vir Biotechnology Conference Call Company Overview - **Company**: Vir Biotechnology (NasdaqGS:VIR) - **Focus Areas**: Infectious diseases and oncology, utilizing the human immune system to combat diseases [3][4] Key Strategies and Developments - **Oncology Programs**: - Development of masked T-cell engagers for metastatic solid tumors, with three clinical stage programs [3] - Recent compelling data from the prostate cancer program (VIR-5500) presented at ASCO GU [5] - Ongoing registrational program in hepatitis delta with initial data expected by the end of the year [4] Prostate Cancer Program (VIR-5500) - **Clinical Data**: - Phase 1 trial involved late-stage metastatic prostate cancer patients, many with poor prognoses [5] - Notable patient case: 63-year-old male with extensive liver metastases showed total obliteration of lesions after 9 weeks of treatment [6] - Achieved 53% PSA 90s and 29% PSA 99s in patients treated with doses above 3,000 micrograms per kilogram [7][12] - **Safety Profile**: - Low levels of cytokine release syndrome (CRS) and off-tumor toxicity, indicating a favorable safety profile [11][12] Competitive Landscape - **Differentiation**: - VIR-5500's dual masking technology allows for targeted action in the tumor microenvironment, potentially setting it apart from competitors [10] - Initial focus on late-line therapy with plans to explore earlier lines of therapy in combination with enzalutamide [15][17] Partnership with Astellas - **Deal Highlights**: - 50-50 profit split in the U.S. and co-promotion agreement, aiming for rapid market entry [20] - Financial terms include $1.7 billion in milestones and royalties, with Astellas covering 60% of global development costs [21] Future Plans - **Clinical Trials**: - Plans to skip Phase 2 and move directly to pivotal trials for VIR-5500 next year [24] - Expansion cohorts to begin in Q2 2026 [24] Other Oncology Programs - **HER2 and EGFR Programs**: - HER2 program showed initial signs of activity with 50% tumor shrinkage in a small cohort [36] - EGFR program is in early stages of dose escalation, exploring multiple indications [43] Hepatitis Delta Program - **Efficacy Data**: - 66% of patients reached undetectable levels after 48 weeks; 90% after 96 weeks [48] - Combination regimen of antibody and siRNA shows significant efficacy compared to competitors [50] - **Market Position**: - Anticipation of increased awareness and diagnosis of hepatitis delta due to competitive landscape [49] Financial Position - **Cash Runway**: - Increased cash position with partnerships and financing, providing runway until Q2 2028 [56] - Focus on oncology and hepatitis delta as key priorities while exploring other programs [57] Market Perception - **Company Transformation**: - Transition from a COVID-focused company to an immuno-oncology company, with a strong vision and promising data supporting this shift [58]

Summary of Vir Biotechnology FY Conference Call Company Overview - **Company**: Vir Biotechnology (NasdaqGS:VIR) - **Focus**: Development of innovative therapies for serious diseases, particularly in oncology and infectious diseases Key Developments - **VIR-5500**: - Recent data disclosed showed impressive efficacy and safety profiles in a trial involving very sick patients, with 95% having pre-taxane treatment and a median of 4 prior therapies [2][3] - **Efficacy Metrics**: - PSA50 rate: 82% - PSA90 rate: 53% - PSA99 rate: 29% - RECIST ORR: 45% in a very sick patient population [4] - **Safety Profile**: - Utilizes a PRO-XTEN masking platform to enhance safety by activating T-cells only at the tumor site, allowing for higher dosing without significant toxicity [5][6] Partnership with Astellas - **Strategic Partnership**: - Astellas selected as a partner due to their experience in prostate cancer and alignment on speed to market [16][17] - The deal includes a 50/50 profit split and a total of $1.7 billion in milestones, with $240 million cash upfront [19] - Vir retains significant involvement in the program, allowing for cash flow to support other projects [18] Future Plans - **Expansion Cohorts**: - Plans to initiate expansion cohorts for late-line monotherapy and early-line combination therapies with enzalutamide [11] - Pivotal trials expected to start next year [11] Competitive Landscape - **T-cell Engagers (TCEs)**: - VIR-5500 positioned as a potential best-in-class TCE for prostate cancer, achieving a favorable balance of efficacy and safety compared to competitors [13] - Other TCEs have shown either high efficacy with toxicity issues or mediocre efficacy with good safety profiles [13] Pipeline Overview - **Clinical Assets**: - Licensed three clinical-stage assets from Sanofi, including HER2 (VIR-5818) and EGFR (VIR-5525), both in phase 1 [23] - Seven preclinical assets utilizing the PRO-XTEN technology are progressing rapidly [24] Hepatitis Delta Virus (HDV) Program - **Tobevibart and Elebsiran**: - Combination therapy showed an 88% target not detected rate after 96 weeks, indicating strong efficacy in treating HDV [30] - Registrational trials ongoing, with initial data expected in Q4 2026 [30] Market Opportunity - **HDV Patient Population**: - Estimated 60,000 viremic patients in the U.S. and double that in Europe, with high potential pricing due to the orphan disease status [34] - Pricing estimates range from $150K to $250K in the U.S. and €60,000 to €150,000 in Europe [34] Financial Position - **Cash Balance**: - Post-Astellas deal, cash balance is $783 million, extending runway into Q2 2028 [37] - Recent equity raise of $173 million to support TCE portfolio [37] Strategic Considerations - **Internal vs. External Development**: - Decisions made on a case-by-case basis, considering market size, competitive landscape, and required capabilities [39][40] Conclusion - Vir Biotechnology is positioned strongly in the oncology space with promising data for VIR-5500 and a strategic partnership with Astellas that enhances its development capabilities and financial flexibility. The company is also making significant strides in addressing unmet needs in HDV treatment, with a robust pipeline and a clear strategy for future growth.

Investment Rating - The report indicates a positive investment outlook for the prostate cancer treatment sector, particularly focusing on PSMA-targeted therapies, with a strategic partnership between Vir Biotechnology and Astellas valued at $1.7 billion [12][16]. Core Insights - Prostate cancer is one of the most common malignancies in men globally, with PSMA being a critical biomarker for diagnosis and treatment. PSMA-targeted therapies, including radioligand therapy and novel T-cell engagers, show significant promise in treating advanced stages of the disease [8][11]. - The report highlights the advancements in PSMA/CD3 T-cell engagers (TCEs), particularly the development of VIR-5500 and JANX007, which utilize shielding peptide technology to enhance safety and efficacy by limiting T-cell activation to the tumor microenvironment [11][20][29]. - Initial clinical data for VIR-5500 shows good tolerability and promising efficacy, with a PSA response rate of 82% in high-dose groups, indicating a strong potential for further development [25][21]. Summary by Sections Section 1: Prostate Cancer and PSMA Targeting - PSMA is highly expressed in prostate cancer cells, making it a key target for both diagnostic and therapeutic interventions. The dual enzymatic activity of PSMA supports its role in promoting tumor aggressiveness [8][9]. - Current PSMA-targeted strategies include radioligand therapies and novel TCEs, which are being actively researched and developed [8][11]. Section 2: Clinical Development of PSMA/CD3 TCEs - The report details the clinical progress of PSMA/CD3 TCEs, noting that early candidates faced challenges due to issues like antibody-drug interactions and systemic toxicity. However, the introduction of shielding peptide technology has shown potential to mitigate these risks [11][12]. - VIR-5500, a leading candidate, has shown positive early-phase clinical trial results, with a strategic partnership established to support its development [16][21]. Section 3: Company Updates and Financials - Vir Biotechnology has secured a $335 million upfront payment from Astellas as part of their collaboration, with potential milestone payments reaching up to $1.37 billion [16][12]. - The report also mentions the financial performance of various biotech companies, highlighting significant revenue growth and strategic partnerships that enhance their market positions [45].

FDA Approvals & Rejections - Armata Pharmaceuticals received FDA QIDP designation for AP-SA02, a bacteriophage-based candidate for complicated Staphylococcus aureus bacteremia, providing five years of market exclusivity and eligibility for Fast Track status [2][3] - Allurion Technologies gained FDA PMA approval for the Gastric Balloon System, a swallowable Smart Capsule that promotes fullness for about four months, targeting patients with a BMI of 30-40 [4][5] - Eton Pharmaceuticals' DESMODA oral solution was approved for managing central diabetes insipidus, with an expected peak annual sales of $30 million - $50 million [9][11] Deals - Gilead Sciences announced the acquisition of Arcellx for $115 per share, totaling an implied equity value of $7.8 billion, enhancing its position in cell therapy [12][13] - Vir Biotechnology entered a global collaboration with Astellas for VIR-5500, receiving $335 million in upfront payments and potential additional milestones of up to $1.37 billion [14][15][16] - Kairos Pharma signed a term sheet to acquire two oncology assets from Celyn Therapeutics, focusing on cancer therapeutics [17][18][20] Clinical Trials - Breakthroughs - MoonLake Immunotherapeutics reported positive Phase 2 trial results for Sonelokimab in axial spondyloarthritis, with 81% of patients achieving an ASAS40 response at Week 12 [21][22] - Novo Nordisk's CagriSema missed its primary endpoint in a Phase 3 trial against Zepbound, showing 23% weight loss compared to 25.5% with Tirzepatide [25][26][27] - Gossamer Bio's seralutinib missed the primary endpoint in the PROSERA Phase 3 study for pulmonary arterial hypertension, showing a placebo-adjusted improvement in Six-Minute Walk Distance [28][30][31] - Argenx's VYVGART met primary goals in the Phase 3 ADAPT OCULUS trial for ocular myasthenia gravis, demonstrating significant improvement in ocular scores [37][38][39]

Core Viewpoint - Vir Biotechnology, Inc. has announced the pricing of its public offering of common stock, aiming to raise $150 million through the sale of 17,647,058 shares at $8.50 per share, with a potential additional option for underwriters to purchase up to 2,647,058 shares [1] Group 1: Offering Details - The public offering consists of 17,647,058 shares priced at $8.50 each, expected to generate gross proceeds of $150 million before expenses [1] - Underwriters have a 30-day option to purchase an additional 2,647,058 shares at the public offering price [1] - The offering is set to close on February 27, 2026, pending customary closing conditions [1] Group 2: Underwriters and Registration - Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, and Barclays are acting as book-running managers for the offering [1] - The shares are being offered under an automatically effective shelf registration statement filed with the SEC on November 3, 2023 [1] Group 3: Company Overview - Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing medicines for serious infectious diseases and cancer [1] - The company's clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers targeting solid tumors [1]

Core Insights - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, highlighting the key trends and catalysts that influence market valuations [1] Group 1: Company and Industry Overview - Edmund Ingham, a biotech consultant with over 5 years of experience, has compiled detailed reports on more than 1,000 companies in the biotech, healthcare, and pharma industries [1] - The Haggerston BioHealth investing group caters to both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, and forecasts for major pharmaceutical companies [1] - The group provides comprehensive financial analyses, including integrated financial statements, discounted cash flow analysis, and market-by-market evaluations [1]

Vir Biotechnology reported a fourth-quarter loss of 31 cents, beating the consensus loss of 41 cents. Sales reached $64.07 million, surpassing the consensus of $23.18 million.The partnership with the Japanese drugmaker announced on Monday aims to advance VIR-5500, an investigational treatment for prostate cancer, which is expected to enhance the company's oncology pipeline as it seeks to address a critical area in cancer treatment to advance PSMA targeting.On Monday, Vir Biotechnology shared new data from t ...

Vir Biotechnology(VIR.US)一度涨超38%，最高触及10.29美元，创逾一年新高。 消息面上，Vir Biotechnology第四季度营收为6407万美元，同比增长417%，市场预期为4416万美元；每 股亏损0.31美元，去年同期每股亏损0.76美元。此外，公司宣布VIR-5500的1期临床试验中取得积极结 果，VIR-5500是一种用于治疗晚期转移性去势抵抗性前列腺癌的在研疗法。(格隆汇) ...

Corporate Overview Presentation February 2026 2026 Vir Biotechnology, Inc. 1 Legal disclaimer Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the therapeutic and commercial potential of Vir Biotechnology's CHD program, as well as Vir Biotechnology's strategy, plans and expectations related thereto; the therapeutic and commercial potential of ...

Economic Indicators - U.S. rate futures indicate a 95.9% probability of no rate change and a 4.1% chance of a 25 basis point rate cut at the March FOMC meeting [1] - The U.S. Conference Board's Consumer Confidence Index is expected to rise to 87.4 in February from 84.5 in January [6] - The U.S. Richmond Fed Manufacturing Index is anticipated to come in at -8 for February, compared to -6 previously [7] Stock Market Performance - Wall Street's main stock indexes ended lower, with IBM dropping over 13% after AI startup Anthropic announced a tool that could modernize programming languages used on IBM systems [3] - Capital One Financial and JPMorgan Chase saw declines of more than 8% and 4% respectively, amid concerns about the economic impact of AI [3] - PayPal Holdings rose over 5% after reports of takeover interest from potential buyers [3] Corporate Earnings - Home Depot, Constellation Energy, and other notable companies are set to release quarterly results [9] - Keysight Technologies surged over 16% in pre-market trading after posting strong FQ1 results and guidance [14] - Vir Biotechnology jumped over 65% in pre-market trading following a licensing agreement with Astellas Pharma [15] Global Trade and Tariffs - President Trump's new 10% global tariffs took effect, with plans for a potential increase to 15% [5] - The European Union has paused the ratification of its trade deal with the U.S. due to uncertainties surrounding the new tariffs [11] - China has called for the U.S. to eliminate unilateral tariffs while expressing willingness for further trade talks [12]